Assembly Biosciences Prices $100M Offering at Discount, Significant Dilution Expected

summarizeSummary

Assembly Biosciences priced a public offering of common stock and pre-funded warrants at a discount, aiming to raise $93.3 million for clinical development and general corporate purposes, which will result in significant dilution for current shareholders.

check_boxKey Events

• Public Offering Priced

  Assembly Biosciences priced an offering of 3,358,602 shares of common stock and pre-funded warrants to purchase up to 415,000 shares of common stock at $26.50 per share.

• Significant Capital Raise

  The offering is expected to generate approximately $93.3 million in net proceeds, which will be used to fund clinical development of pipeline candidates and for general corporate purposes.

• Dilution for Existing Shareholders

  The offering represents a potential dilution of approximately 23.7% to the outstanding share count, with an immediate dilution of $11.34 per share to new investors in book value.

• Priced at a Discount

  The offering price of $26.50 per share is an 8.6% discount compared to the current stock price of $29.00.

auto_awesomeAnalysis

Assembly Biosciences has finalized the terms and pricing for a public offering, selling 3,358,602 shares of common stock and pre-funded warrants for up to 415,000 additional shares. This offering, priced at $26.50 per share (an 8.6% discount to the current market price), is expected to generate approximately $93.3 million in net proceeds. The transaction represents a substantial capital raise, but also significant potential dilution of approximately 23.7% to existing shareholders, as the company issues new shares to fund clinical development and for general corporate purposes. This follows the universal shelf registration filed on March 19, 2026.